Celltrion Pharm launches three biosimilars in Korea

Celltrion Pharm Inc. CI

Celltrion Pharm Inc. announced on Monday that it has launched three biosimilar drugs in South Korea.

Omlyclo, a biosimilar of Xolair, is a treatment for allergic asthma and chronic idiopathic urticaria. The drug is priced at 102,960 won ($76.9) for 75 milligrams (mg) and 195,079 won for 150 mg, about 28 percent cheaper than the original drug.

Omlyclo is the first of its kind to be launched domestically.

Steqeyma, a biosimilar of Stelara, is for the treatment of autoimmune diseases. It covers all indications for Stelara, including plaque psoriasis, psoriatic arthritis, Crohn‘s disease and ulcerative colitis.

Its pre-filled syringe formulations are priced at 1.29 million won and 1.34 million won according to the volume, about 26 percent cheaper than the original drug.

Eydenzelt, a biosimilar of Eylea, is for neovascular (wet) age-related macular degeneration, macular edema secondary to retinal vein occlusion, diabetic macular edema and visual impairment due to myopic choroidal neovascularization.

It is priced at 330,000 won, about 34 percent less than the original. The biosimilar drug has a shelf life of 36 months, longer than competing products based on stability testing.

Celltrion Pharm aims to increase market penetration through product-specific academic symposia for healthcare professionals and collaborations with strategic partners in disease-specific sales and marketing.